These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27467121)

  • 1. Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors.
    Minami H; Ando Y; Ma BB; Hsiang Lee J; Momota H; Fujiwara Y; Li L; Fukino K; Ito K; Tajima T; Mori A; Lin CC
    Cancer Sci; 2016 Oct; 107(10):1477-1483. PubMed ID: 27467121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
    Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
    Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
    Stathis A; Hess D; von Moos R; Homicsko K; Griguolo G; Joerger M; Mark M; Ackermann CJ; Allegrini S; Catapano CV; Xyrafas A; Enoiu M; Berardi S; Gargiulo P; Sessa C;
    Invest New Drugs; 2017 Dec; 35(6):766-772. PubMed ID: 28317088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.
    Esaki T; Hirai F; Makiyama A; Seto T; Bando H; Naito Y; Yoh K; Ishihara K; Kakizume T; Natsume K; Myers A; Doi T
    Cancer Sci; 2019 Apr; 110(4):1340-1351. PubMed ID: 30724423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
    Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
    Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
    Pietanza MC; Litvak AM; Varghese AM; Krug LM; Fleisher M; Teitcher JB; Holodny AI; Sima CS; Woo KM; Ng KK; Won HH; Berger MF; Kris MG; Rudin CM
    Lung Cancer; 2016 Sep; 99():23-30. PubMed ID: 27565909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.
    Kieran MW; Chisholm J; Casanova M; Brandes AA; Aerts I; Bouffet E; Bailey S; Leary S; MacDonald TJ; Mechinaud F; Cohen KJ; Riccardi R; Mason W; Hargrave D; Kalambakas S; Deshpande P; Tai F; Hurh E; Geoerger B
    Neuro Oncol; 2017 Oct; 19(11):1542-1552. PubMed ID: 28605510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors.
    Zhou J; Quinlan M; Hurh E; Sellami D
    J Clin Pharmacol; 2016 Nov; 56(11):1406-1415. PubMed ID: 27095306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
    Ruiz-Borrego M; Jimenez B; Antolín S; García-Saenz JA; Corral J; Jerez Y; Trigo J; Urruticoechea A; Colom H; Gonzalo N; Muñoz C; Benito S; Caballero R; Bezares S; Carrasco E; Rojo F; Martín M
    Invest New Drugs; 2019 Feb; 37(1):98-108. PubMed ID: 29948356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
    Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
    Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
    Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
    Migden MR; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kudchadkar R; Trefzer U; Gogov S; Pallaud C; Yi T; Mone M; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Chang AL; Cornélis F; Lear JT; Sellami D; Dummer R
    Lancet Oncol; 2015 Jun; 16(6):716-28. PubMed ID: 25981810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert opinion on sonidegib efficacy, safety and tolerability.
    Villani A; Fabbrocini G; Costa C; Ocampo-Garza SS; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2021 Aug; 20(8):877-882. PubMed ID: 33888008
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
    Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
    Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series.
    Villani A; Costa C; Fabbrocini G; Ruggiero A; Scalvenzi M
    J Am Acad Dermatol; 2021 Apr; 84(4):e211-e212. PubMed ID: 33301802
    [No Abstract]   [Full Text] [Related]  

  • 18. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.
    Bendell JC; Varghese AM; Hyman DM; Bauer TM; Pant S; Callies S; Lin J; Martinez R; Wickremsinhe E; Fink A; Wacheck V; Moore KN
    Clin Cancer Res; 2018 Jul; 24(14):3253-3262. PubMed ID: 29636360
    [No Abstract]   [Full Text] [Related]  

  • 19. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
    Quinlan M; Zhou J; Hurh E; Sellami D
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.
    Doi T; Lee KH; Kim TM; Ohtsu A; Kim TY; Ikeda M; Yoh K; Gallo Stampino C; Hirohashi T; Suzuki A; Fujii Y; Andrew Williams J; Bang YJ
    Cancer Med; 2016 Jul; 5(7):1454-63. PubMed ID: 27075560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.